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Summary
We previously reported that natural killer cell stimulatory factor (NKSF), a heterodimeric
lymphokine purified from the conditioned medium ofhumanB lymphoblastoid cell lines, induces
interferon y (IFN-y) production from resting peripheral blood lymphocytes (PBL) and synergizes
with interleukin 2 in this activity. In this study, we show that human NKSF induces IFN-y
production from both resting and activatedhumanPBL and from freshly isolated murine splenocytes .
Human T andNK cells produce IFN-,y in response toNKSF, but restingPBL require the presence
of nonadherent human histocompatibility leukocyte antigens DR' (HLADR+) accessory cells
to respond to NKSF. The mechanism(s) by which NKSF induces IFN-y production results in
accumulation of IFN-y mRNA, is insensitive to cyclosporin A, and synergizes with those mediated
by phytohemmagglutinin, phorbol diesters, anti-CD3 antibodies, and allogeneic antigens, but
not by Ca2+ ionophores. The ability of NKSF to directly induce IFN-,y production and to
synergize with other physiological IFN- ,y inducers, joined with the previously described ability
to enhance lymphocyte cytotoxicity and proliferation, indicates that this lymphokine is a powerful
immunopotentiating agent .
N
atural killer cell stimulatory factor (NKSF)' is a cyto-
kine that was identified and purified from the condi-
tioned medium of B lymphoblastoid cell lines. The NKSF
protein is a 70-kD disulfide-linked heterodimer composed of
a MAD and a 40-kD chain. NKSF induces IFN-,y produc-
tion from PBLs, augments NK cell-mediated cytotoxicity,
and enhancesT cell proliferation induced by lectins and phorbol
diesters (1) . We have cloned and sequenced the two genes
encoding NKSF and have shown that the biological activity
of recombinant NKSF is identical to those we reported for
purified natural NKSF, confirming that NKSF is a novel
cytokine (1a) . Recently, cytotoxic lymphocyte maturation
factor (CLMF) was purified by Stern et al . (2) from the con-
' Abbreviations used in this paper . CLMF, cytotoxic lymphocyte maturation
factor ; C&A, cyclosporin A ; EMC, encephalomyocarditis; F/H, Ficoll-
Hypaque; LT, lymphotoxin; MLC, mixed leukocyte culture; NKSF, natural
killer cell stimulatory factor ; PDBu, phorbol dibutyrate ; PKC, protein
kinase C ; TPA, tetradecancylphorbol acetate.
ditioned medium of the human B lymphoblastoid cell line
NC-37 ; this factor appears to have physicochemical charac-
teristics, biological activity, and NH2-terminal amino acid
sequences identical to those of NKSF .
Regulation of IFN-,y production during inflammation or
an immune response is of central importance to the mecha-
nisms ofboth adaptive and nonadaptive resistance (3-6) . Thus,
the ability ofNKSF to induceIFN-y production from PBL
may represent one of the most biologically significant func-
tions of this lymphokine. IFN-,y is not constitutively pro-
duced by resting PBL . However, both NK and T cells are
induced to secrete IFN-y in response to 1172 stimulation (7-9) .
NKSF synergizes with IL-2 in inducing IFN- ,y production
from PBL (1) . T cells also produce IFN-,y upon specific ligand
interaction with TCR (7) ; this interaction can be partly
replaced by antibodies toTCR or to the TCRassociatedCD3
complex (10) . NK cells produce IFN-y upon crosslinking
of the type III receptor for Fc of IgG (FcyRIII or CD16)
(11) . Similar to NKSF, TCR-CD3 and CD161igands syner-
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cells, respectively. The effect of these IFN-y inducers can be
mimicked by lectins such as PHA (12-14), byphorboldiesters
(12, 15, 16), and by Caz+ ionophores (17, 18).
In this study, we have characterized the IFN-y-inducing
activity of NKSF andcompared it to otherinducers of IFN-y.
We report that humanNKSF induces IFN-y production from
resting and activatedhumanT andNK cells, as well as from
mouse lymphocytes. NKSF-induced IFN-y production in
human PBL is mediated via a mechanism that is insensitive
to cyclosporin A (CsA), synergizes with several otherIFN-y
inducers, andrequires theparticipation of nonadherent HLA
DR+ accessory cells.
Materials and Methods
Cytokines and Reagents. rID2 (10' U/mg) was generously
provided by Dr. T Taguchi (Osaka University, Osaka, Japan) and
Takeda Chemical Industrial Industry, Inc. (Osaka,Japan). Thefol-
lowing reagents were purchasedfrom commercial sources: PHA-M
(Wellcome Diagnostics, Dartford, England); 12-O-tetradecanoyl-
phorbol 13-acetate (TPA; Sigma Chemical Co., St . Louis, MO);
phorbol-12,13-dibutyrate (PDBu; Chemsyn Science Laboratories,
Lexena, KS); Cal+ ionophore A23187 (Sigma Chemical Co., St.
Louis, MO); cyclosporin A (C&A; Sandoz Ltd., Vienna, Austria).
Preparations ofNKSF.
￿
NKSF waspurified as described in detail
by Kobayashi et al. (1) from serum-free conditioned medium of
48-h PDBu-induced RPMI 8866 cell cultures. TheIFN-y induc-
tion assay(described below) was used to quantitate NKSF activity
in semi-purified and purified preparations. 1 U of NKSF activity
is defined as the amount required to induce half-maximal IFN-y
production. Thepurified NKSF preparation used in this studyhad
a specific activity of 4 x 106 U/mg protein. In many of the ex-
periments described, we used semi-purified preparations of NKSF
obtained after a two-step purification procedure: (a) hydroxylapa-
tite chromatography and (b) Mono Q ion exchange chromatog-
raphy performed as previously described (1).
Antibodies.
￿
mAbs B36.1(anti-CD5, IgG2b),B67.1(anti-CD2,
IgG2a), B73.1(anti-CD16, IgGl); B52.1(anti-CD14, IgM);B33.1
(anti-HLADR, nonpolymorphic determinant, IgG2a);B133.1 and
B133.5 (anti-IFN-y, IgGl)were produced andcharacterizedin our
laboratory. Antibody OKT3 (anti-CD3, IgG2a) wasproduced from
hybrid cells purchased from American Type Culture Collection
(ATCC) (Rockville, MD) and antibody 3G8 (anti-CD16, IgGl)
was kindly provided by Dr. J. Unkeless (Mount Sinai School of
Medicine, New York, NY). Culture supernatants or antibodies
purified from ascitic fluids were used at predetermined optimalcon-
centrations. Goat anti-IL2 antiserum (>105 neutralizing U/ml)
and the affinity-purified goat anti-mouse IgG were produced in
ourlaboratory An NKSF neutralizing antiserumwasobtained from
a rabbit immunized with the purified recombinant 40-kD chain
of NKSF. FITC-labeled goat F(ab')2 anti-mouse Ig was purchased
from Cappel Laboratories (Cochranville, PA) andused after adsorp-
tion to human IgG.
Cell Preparations.
￿
Peripheral bloodwas obtained by venipunc-
ture from adult healthy donors using heparin as anticoagulant.
PBMC were separated on Ficoll-Hypaque (F/H) density gradient
(Lymphoprep; Nyegaard and Co., Oslo, Norway). PBL were pre-
pared from PBMC after partial depletionof monocytes by adher-
ence to plastic (45 min, 37°C). Different PBL subsets and acces-
sory cells were purified from the PBL preparations by (a) positive
andnegative selection, as indicated, usingmAbs specific forleuko-
870 Interferon y Induction by Natural Killer Cell Stimulatory Factor
cyte differentiation antigens, indirect antiglobulin rosetting, and
F/H gradient separation, as described (19), or (b) fluorescence-
activated cell sorting with a FACS IV® flow cytometry system
(BectonDickinson & Co., Mountain View, CA), after staining by
indirect immunofluorescence using FITC-labeled goat F(ab')z
anti-mouse Ig. PHAblasts were prepared by culturingPBMC in
1% PHA-M for 5 d at a starting concentration of 106 cells/ml.
NK cells (CD3 - CD5- CD14-) and T cells (CD16- CD56- and
CD14-) were purified by negative selection using theindirect an-
tiglobulin rosetting method from 10-d cultures ofPBMC with y-ir-
radiated (50Gy) RPMI 8866 cells, as described (20). The human
B lymphoblastoid cell line, RPMI 8866, wasmaintained in RPMI
1640 (Flow Laboratories Inc., Rockville, MD) supplemented with
10% FCS (FlowLaboratories Inc.); it wasfree of mycoplasma con-
tamination on repeated testing. Murine splenocytes were obtained
from spleens of 4-6-wk-old BALB/c female mice and depleted of
erythrocytes by lysis with hypotonic medium. Surface Ig+-de-
pleted cells were obtainedby negative selection using antiglobulin
rosetting and F/H gradient separation as described (21).
IFN-y Induction Assay. The different leukocyte preparations
(106cells/200 pd/well) were incubated (37°C, 5% C02) for 18 h
with various inducers in round-bottomed 96-well microtiter plates
(Costar, Cambridge, MA). Stimulation with anti-CD3 antibodies
was performed in wells coated with various dilutions of purified
OKT3 antibody. Theantibody dilutedin 100td of0.1 Mcarbonate
buffer, pH 9.4, was incubated overnight at 4°C in flat-bottomed
bacteriological %-well microtiter plates; thewellswere washed three
timeswith PBSimmediately before the different leukocyte prepa-
rations were added and the plates incubated (37°C, 5% CO2,
18 h). After incubation, triplicate 50 pl of cell-free supernatant was
collected from each well and IFN-y was measured as described
below.
Human Mixed Leukocyte Culture (MLC).
￿
5 x 104 responder
PBMC were mixed with 105 irradiated (45 Gy) stimulator PBMC
from autologous or unrelatedallogeneic donors in 200iclof RPMI
1640 supplemented with 10% heat-inactivated human AB serum
in round-bottomed microtiter plates. After 6 d of incubation at
37°C, cell-free supernatant fluids were collected and IFN-y was
measured by RIA.
IFNAssays.
￿
RIA for human IFN-y was performed as previ-
ously described (22). Sensitivity of the assay is 0.5 U/ml IFN-y
and no crossreaction with TNF, lymphotoxin (LT), or other spe-
cies of IFN is observed. Murine IFN-y wasmeasured usingacom-
mercialELISA (Amgen, Thousand Oaks, CA): sensitivity of the
assayis 12 U/ml IFN-y. Antiviralactivity in thecell-free superna-
tants of murine cell cultures was assessed by inhibition of the
cytopathic effect ofencephalomyocarditis (EMC)viruson the mouse
fibroblast cell line, LF2, as described (23); assays were quantitated
using the NIH mouse IFN reference as standard.
In Situ Hybridization.
￿
Cell preparations were deposed on mi-
croscope slides using a cytocentrifuge. 3'S-labeled riboprobes were
prepared from plasmids containing a5' 80-bpfragment ofthehuman
IFN-y cDNA inserted into the PstI restriction site of the pGem3
vector. Plasmids were linearized at the EcoRl and HindIIIrestric-
tion sites andtranscribed into mRNA-complementary (antisense)
andmRNAlike (sense)probes using IIS-UTP (New England Nu-
clear, Wilmington, DE) and a riboprobe kit (Promega Biotec,
Madison, WI) according to the manufacturer's suggestions. Hy-
bridization wascarriedout overnightat 45°C as describedby Harper
et al. (24). Slides were washed twice (10min at room temperature)
in 2x SSC (lx
￿
= 0.15 M NaCl, 0.015 M NaCitrate, pH 7.0)
andfour times (15min, 55°C)in 0.25X SSC,1mM EDTA,1 mM
DTT Nonhybridized probe was digested with 40 FAg/ml RNaseA (Sigma Chemical Co.) in 10 mM tris, pH 8, 0.3 M NaCl for
30 min at 37°C. The slides were then washed (30 min, 55°C)twice
in 50% formamide, 2x SSC, 1 mM DTT, and finally, in 2x SSC,
1 mM DTT After dehydration in graded ethanol solutions con-
taining 0.3 M ammonium acetate and air drying, the slides were
dipped in NTB3 nuclear trackemulsion (Eastman Kodak Co., Roch-
ester, NY) diluted 1:1 with 0.6 M ammonium acetate. After ex-
posure for 3-7 d at 4°C, the slides were developed with Kodak
D-19 developer,fixedwith Kodak Rapidfix, and counterstained with
hematoxylin and eosin.
Northern Blot Hybridization.
￿
Cytoplasmic RNA samples were
prepared from induced and uninduced cells using the NP-40 1ysis
method as described (25). RNA samples were fractionated in a 1%
agarose-formaldehyde gel. Briefly, the fractionated RNA was trans-
ferred to nylon membrane filters (Schleicher & Schuell, Inc., Keene,
NH) by capillary action and crosslinked to filters by UV irradia-
tion. The human IFN-,y cDNA probe (restriction fragment at the
Pstl site from a construct in pSWIF) and the human ß-actin cDNA
probe in pBR322 (grown in plasmid form, kindly provided by Dr.
Roberto Weinmann, Wistar Institute), were labeled with 'zP-
cxCTP (-3000 Ci/mmol; New England Nuclear) using a random
priming kit (Amersham Corp., Arlington Heights, IL). Filter-bound
RNA was hybridized according to Singh and Jones (26) at 42°C
for 16 h with labeled probe at 1-2 x 106 cpm/ml hybridization
solution: 4x SET (0.1 M NaCl, 6 mM tris-Cl, pH 7.5, 0.4 mM
EDTA, pH 7.4), 0.1% sodium pyrophosphate, 0.2% SDS, 10%
dextran sulfate, 500 FAg/ml heparin sodium salt grade II from por-
cine intestinal mucosa (Elkins-Sinn, Inc., Cherry Hill, NJ), and
100 tcg/ml denatured salmon sperm DNA. After hybridization,
the filters were washed three times at 37°C with 2x SSC, 0.1%
SDS, once at 65°C with O.1x SSC, 0.1% SDS for 45 min, and
then exposed to X-Ornat AR film (Eastman Kodak Co.) between
double intensifying screens (DuPont Co., Wilmington, DE) at
-70°C.
Results
IFN--y Production by PBL Induced with NKSF .
￿
We (1) pre-
viously reported that purified NKSF induces IFN--y produc-
tion in freshly isolated PBL in a dose-dependent manner and
synergizes with rIL2 in this activity. To determine if NKSF
synergizes with other inducers ofIFN-y, PBL were incubated
(18 h) with increasing concentrations of purified NKSF in
the absence or presence of PHA, phorbol diesters, Ca2+
ionophores, or anti-CD3 (OKT3) antibodies; IFN-y was
quantitated by RIA in the cell-free supernatants. NKSF, in
a dose-dependent manner, synergized with PHA (Fig. 1 A),
the phorbol diesters TPA (Fig. 1 B) and PDBu (not shown),
and anti-CD3 antibodies (Fig. 1 C) at all concentrations tested,
to induce IFN-y secretion. rIL2, which synergizes with NKSF
in inducing IFN--y production, did not synergize with PHA
or phorbol diesters (not shown) . The Ca 2+ ionophores,
A23187 (Fig. 1 D) and ionomycin (not shown), efficiently
synergized with phorbol diesters in inducing IFN--y produc-
tion, but the same concentrations did not synergize with
NSKF and inhibited IFN--y production induced with high
NKSF concentrations.
To determine whether PHA or TPA synergizes with NKSF
via the induction of íL2 production, PBL were stimulated
with NKSF, alone, or in combination with PHA or TPA,
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Figure 1 .
￿
IFN-.y production by PBL induced with NKSF. Cells were
incubated with the indicated concentrations of purified NKSF for 18 h
at 37°C in the absence (") or presence of (A) PHA at (p) 0.4 tug/ml;
(/) 1.1,ug/ml, (A) 3.3. lAg/ml, (*) 10,ug/ml; (B) TPA at (7) 10- 10
M, (/) 10 -9 M, (A) 10 -8 M, (*) 10-7 M; (C) OKT3 plated at (p)
0.2 jug/well, (M) 0.8 t~g/well; and (D) (p) 0.2 ug/ml A23187, (M) 10-7
M PDBu, (0) 10-7 M PDBu and 0.5 ttg/ml A23187. IFN--y was mea-
sured by RIA in cell-free supernatant fluids.
in the presence of a goat anti-IIr2 antiserum (Fig. 2) . The
antiserum completely suppressed IFNJy production in response
to 100 U/ml of rIL2 and partially (22%), but significantly
reduced IFN-y production induced by NKSF alone. IFN-y
production in response to NKSF and rIL2 was inhibited to
the levels observed with NKSF alone. No inhibition ofIFN--y
production by anti-í1r2 antiserum was observed when PBL
were stimulated with PHA, with or without NKSF, or with
phorbol diesters plus NKSF. However, significant inhibition
was observed when PBL were stimulated by phorbol diesters
alone. Preimmune goat serum did not inhibit IFN-y produc-
tion induced by any of the stimuli used (not shown) .
To determine whether CSA, which suppresses anti-CD3
and lectin-induced IFN--y and 11,2 production (27) in T cells,
affects NKSF-induced IFN-y production, PBL were stimu-
lated with NKSF and other stimuli in the presence of CsA.
As expected, CsA (1 hg/ml) significantly inhibited IFN-y
production in PBL stimulated with anti-CD3 (OKT3) anti-
bodies but not with rIL2 (Table 1). At the same concentra-
tion, CsA did not inhibit IFN--y productioninducedby NKSF
with or without rIL2 (Table 1), but partially inhibited IFN-y
production induced by PHA or TPA, alone or in synergy
with NKSF (not shown).
Neutralization ofIFN-y-inducing Activity by Rabbit Antiserum
Against Recombinant NKSF. Results in Table 2 show that
a 1:160 dilution of the anti-40-kD chain antiserum completely
blocks the IFN--y production induced by semi-purified NKSF,
alone or in synergy with rIL2, without significantly affectingFigure 2 .
￿
Effect ofgoat anti-IL2 on IFN-y induction by NKSF in PBL.
PBL were incubated for 18 h at 37°C with 2.5 U/ml semi-purifiedNKSF
alone or in combination with 100 U/ml rIIJ2, 10 ug/ml PHA, or 10 -7
M PDBu in the absence (solid bars) or in the presence (hatched ban) of a
1/100 dilution ofgoat anti-human 11,2 antiserum . IFN-y productionwas
measuredby RIA . Results are expressed as mean ± SE ofresults obtained
with n different donors . p values (IFN-y production in cultures in the
absence versus presence ofanti-IIb2) were calculated using the Student t test.
IFN-y production induced by rIL2 . Preimmune serum had
no effect . These results show that NKSF is the only factor
with IFN-y-inducing activity present in the semipurified
preparations of NKSF.
Table 1.
￿
Effect of CsA on IFN-y Production by Human PBL
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" IFN-y was measured by RIA in the cell-free supernatant fluids col-
lected from PBL cultured (18 h, 37°C) in the presence of the indicated
inducers, with or without CsA.
tp of the comparison between IFN-y levels in cell-free supernatant fluids
from PBL cultured with or without CsA, Student t test . NS, not sig-
nificant, p > 0.05 .
S Mean ± SD of results obtained with three different PBL preparations .
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Table 2.
￿
Inhibition ofNKSF Activity by Rabbit Antiserum
Against Recombinant NKSF 40-kD Chain
* PBLfrom onedonor were incubated 18 h at 37°C with the indicated
inducer in the presence or not of a 1:160 dilution of preimmune rabbit
serum or rabbit antiserum against purified recombinant 40-kD chain of
NKSF. The results are representative of four experiments performed .
t The NKSF used was a semi-purified preparation, as described in
Materials and Methods .
Requirement ofAccessory Cells for IFN-y Production byPBL
in Response toNKSF . Plastic adherent PBMC, total nonad-
herent PBL, and the HLADR+ andDR- PBL populations
prepared by indirect rosetting were cultured with increasing
concentrations of NKSF. As shown in Fig. 3, similar levels
ofIFN-y were produced byPBL or byPBL depleted ofmono-
cytes after a second adherence or by removal ofCD14+ cells.
PBL depleted of HLADR+ cells produced significantly
lower levels of INF-y, but removal of CD20+, CD21+ B
cells from PBL did not result in decreased IFN-y production
in response to NKSF (not shown) . Adherent cells, containing
>90% CD14+ monocytes (28), were unable to reconstitute
IFN-y production (Fig . 3) . IFN-y production was restored
0.0 0 .1 0.5 2.5
NKSF, U/ml
Figure 3.
￿
Requirement ofHLADR+ accessory cells forIFN-'Y produc-
tion by PBL in response toNKSF. The different subpopulations were sepa-
rated from nonadherent PBMC by indirect rosetting and incubated with
the indicated concentrations ofsemi-purifiedNKSF for 18 h at 37°C. (O)
PBL, (") CD14- cells, ([I) HLADR- cells with added 10% HLA-DR+
cells, (p) HLA-DR - cells, (") HLA-DR- and 10% adherent PBMC,
and (/) HLA-DR+ cells .
Inducer' No CsA
IFN-y
(U/ml)
CsA (1 ug/ml) pt
None 11.1 ± 6.45 2.33 ± 1 .3 NS
Anti-CD3
(1 P,g/well) 1,567.3 ± 244.7 268 .2 ± 152.5 0.01
rIL-2 (100 U/ml) 1,298.7 ± 379.9 1,052.5 ± 235.1 NS
NKSF (2.5 U/ml) 1,482 .3 ± 374.6 1,183.0 ± 267.0 NS
NKSF + rIL-2 3,023.3 ± 328.2 2,997.7 ± 190.2 NS
Inducer' Medium
IFN-'y
Preimmune Serum
Anti-40-W
Serum
U/ml
None <0.5 1 .9 <0.5
rIL-2, 100 U/ml 3.4 3.0 4.0
NKSFt, 1 U/ml 28.0 47.0 <0.5
rIL-2 + NKSF 744.0 540.0 20.0E
I
Z
u_
Stimulator Cells
Figure 4.
￿
Effect of NKSF on IFN-yproduction in MLC. PBMC were
cultured with irradiated PBMC (105/200 Al) from autologous or al-
logeneic donors for 6 d at 37°C in the absence (solid bars) or presence (hatched
ban) of 0.5 U/ml purified NKSF. Cell-free supernatant fluids were col-
lected and IFN-y was measuredby RIA. Results obtained with responder
cells from three donors, A, B, and C, are shown in A, B, or C, respec-
tively. Ax, Bx, Cxindicate the irradiated stimulator cells from the same
three donors.
only when the HLA-DR- population was reconstituted
with 10% nonadherent HLA-DR' cells. Neither the non-
adherent HLADR's cells nor the adherent cell populations
produced IFN-y when stimulated with NKSF. Northern blot-
ting (not shown) of RNA extracted from HLA-DR - and
HLADR+ cells, purified by indirect rosetting from total
PBL after stimulation for 18 h with NKSF, showed IFN-y
mRNA accumulation only in the HLA-DR - subset, dem-
onstrating that the HLA-DR - cells are the INF-y-pro-
ducing cells, and that the HLADR+ cells act as accessory
cells.
Production of IFN-y in Human MLC in the Presence of
NKSF. NKSF was added to MLC at the beginning ofcul-
ture and IFN-y in the supernatants was measured after 6 d
(Fig. 4). In the absence of added NKSF, cultures stimulated
by allogeneic but not autologous cells produced IFN-y at
levels lower than 40 U/ml. In the presence of NKSF, allogeneic
cultures produced between 300 and 1,000 U/ml of IFN-'y,
whereas autologouscultures produced no more than 30 U/ml
of IFN-y. In addition, when cells collected from a primary
MLC at day 14 were restimulated with the specific allogeneic
cells in a secondary MLC, INF-y productionin cultures stimu-
lated in the presence of NKSF were higher than in control
cultures (not shown).
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Table 3.
￿
IFN-y mRNA Accumulation in Peripheral Blood T
and NK Cells as Detected by In Situ Hybridization
" PBL were cultured for 18 h at 37°C with the indicated inducers and
the different subsets were separated by fluorescence activated cell sorting
after indirect immunofluorescence with antibodies anti-CD3 (OKT3) or
anti-CD16 (3G8) and FITC-labeled goat F(ab')Z anti-mouse Ig. Sorted
cells were cytocentrifuged on slides for in situ hybridization.
t 150 cells in three replicate slides hybridized with antisense 35S-labeled
IFN-y riboprobe were counted. Control hybridization slides with sense
probe showed 2.2 ± 2.1 grains/cells, and no cells with more than 10
grains/cells.
5 A proportion of cells contained > 100 grains per cell and their exact
number could not be accurately determined. These cells have been in-
cluded in the calculation of average values as having 100 grains/cell; there-
fore, these numbers represent a minimum estimate of the average number
of grains per cell.
IFN--y Production by PeripheralBlood Tand NK CellsStimu-
latedwith NKSF . Preparations enriched in T and NK cells
were obtained from PBL by positive or negative selection using
anti-CD3 or anti-CD16 antibodies and indirect rosetting. The
cells were stimulated with NKSF, alone or in combination
with rIL2. Positively selected cells with either antibody were
poor producers of IFN-y, probably because of the absence
of accessory cells in the preparations. However, when HLA
DR+ accessory cells were added to the enriched cell prepa-
rations, similar levels of IFN-y were detected in both the
enriched T (CD3+ or CD16 - ) and NK cell (CD3 - or
CD16+) preparations (not shown) .
IFN-y production in PBL was analyzed at the single cell
levelby in situ hybridization. Total PBL were stimulated for
18 h with NKSF, rIL2, or NKSF plus rIL2. CD3 + or
CD3 - and CD16+ or CD16 - cell populations were sepa-
rated by fluorescence activated cell sorting after staining by
indirect immunofluorescence with antibodies OKT3 and 3G8,
respectively. Accumulation of IFN-y mRNA in these popu-
lations was analyzed by in situ hybridization (Table 3). IFN-y
PBL
subpopulation" Inducer
Percent positive
cells (>10
grains/cells)#
Grains per
positive cell
mean ± SD
Total None 0 N/A
CD16+ NKSF (2.5 U/ml) 1.8 38.3 ± 25 .5
CD16- NKSF (2.5 U/ml) 1.9 64.7 ± 38.1
CD3+ NKSF (2.5 U/ml) 1.6 52.6 ± 29.7
CD3" NKSF (2.5 U/ml) 6.2 57.7 ± 34.1
CD16+ rIL-2 (100 U/ml) 4.1 24.2 ± 36.7
CD16- rIL-2 (100 U/ml) 2.1 51.5 ± 67.6
CD3' rIL-2 (100 U/ml) 0.9 53 .3 ± 50.0
CD3 - rIL-2 (100 U/ml) 1.7 30.9 ± 20.5
CD16+ NKSF + rIL-2 10.3 81 .5 ± 56.85
CD16 - NKSF + rIL-2 14.2 89 .4 ± 67.46
CD3' NKSF + rIL-2 6 .4 82 .7 ± 69.05
MY NKSF + rIL-2 16.2 70.6 ± 45.25Table 4.
￿
IFN-y Production by Cultured T and NK Cells
Inducer*
￿
T cells*
￿
NK cells
U/ml
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Cellswere cultured (5 x 106/ml, 200 Al/well) with the indicated in-
ducers for 18 h at 37°C, and IFN-7 in the cell-free supernatant fluid was
quantitated by RIA.
t T cells (CD16- , CD56- , CD14 -) and NK cells (CD3- , CD5 - ,
CD14-) were purified usingindirect antiglobulin rosetting and gradient
centrifugation from 10-d culture of PBL stimulated with irradiated RPMI
8866 cells. T cells preparation were >95% pure and NK cell preparation
>98% pure.
S Mean ± SD of three experiments.
mRNA was detected in a small proportion of T and NK
cells induced with NKSF or rIIr2 (Table 3). The number of
positive cells (> 10 grains per cell) in cultures treated with
NKSF or rIL2 alone ranged from 1.5 to 6.5%; the number
of positive cells detected in cultures from both cell types treated
with NKSF plus rIL2 ranged from 7.5 to 16%. In addition,
the highly positive cells in cultures stimulated with NKSF
and rIL2 contained a much greater number of grains than
the highly positive cells in cultures stimulated with NKSF
or rIL2 alone (not shown).
Lastly, IFN-y production was measured in T and NK cell
preparations purified from 10-d cocultures of PBL with the
irradiatedB lymphoblastoid cell line, RPMI-8866; these popu-
lations were treated with NKSF, in the absence or presence
of rIL2, for 18 h. As shown in Table 4, both T'and NK
cells produced IFN-y in response to NKSF and/or rIL2 stim-
ulation.
IFNq mRNA Accumulation in PBLandPHA-activatedBlasts
Stimulated with NKSF. To determine if resting and activated
lymphocytes respond to NKSF with the same kinetics, we
tested the ability of NKSF to induce IFN-y in PBL versus
PHAactivated T cell blasts. PHA blasts contain >98%
CD3+ T cells with variable proportions of CD4' and C138'
cells, as detected by indirect immunofluorescence. More than
90% of these cells are CD25+, CD71+, and HLADR+
(not shown); PHA blasts do not proliferate but accumulate
in the G1 phase of the cell cycle after 5 d in culture. How-
ever, they are rapidly induced to proliferate in response to
IL2 (not shown).
PBL and PHA blasts were stimulated for 1, 2, 4, and 24 h
in the presence of NKSF and/or rIL2. Cytoplasmic RNA,
extracted at each time point, was probed for IFN-y mRNA
by Northern blot hybridization and IFN-y was measured in
Table 5.
￿
NKSF-induced Production of IFN-y by Total and
sIg- Mouse Splenic Lymphocytes
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Antiviral activity
(Producer cells)
"` Total unseparated or sIg- splenocytes from BALB/c mice (5 x 106
cells/ml) were incubated for 18 h at 37°C in the presence of the indi-
cated inducers.
t Antiviral activity in the cell-free supernatant fluids was measured by
inhibition of the cytopathic effect of EMC virus on LFZ routine
fibroblasts.
the cell-free supernatant fluids of the 24-h cultures. NKSF,
alone or in combination with rIL2, induced PHA blasts to
secrete IFN-y albeit at consistently lower levels than observed
with PBL (Fig. 5 A). Both PBL and PHA blasts accumu-
lated IFN-y mRNA in response to NKSF and/or rIL2 stim-
ulation, although the activated cells displayed significantly
earlier kinetics of mRNA accumulation than PBL (Fig. 5
A). On average, IFN-y mRNA was detectable in PHA blasts
after 1 h of stimulation and reached peak levels 4-8 h post-
induction whereas maximal levels of IFN-y mRNA were de-
tected in PBL after 24-h culture. Identical results were ob-
tained in PHA blasts using purified (Fig. 5 B) NKSF at 4 h
of induction.
IFN-y Production by Human NKSRtreated Mouse Lympho-
cytes. To test whether human NKSF is effective across spe-
cies barriers on mouse lymphocytes, total splenocytes and
spleen cells depleted of surface Ig+ (sIg+)-B cells by an-
tiglobulin indirect rosetting and density gradient were ob-
tained from adult BALB/c mice and incubated for 18 h with
increasing concentrations of human NKSF, alone or in com-
bination with 1,000 U/ml of human rIL2. The supernatants
were tested for antiviral activity, as measured by inhibition
of the cytolytic effect of EMC virus on mouse fibroblast LF2
cells (Table 5) and for IFN-y concentration by ELISA (not
shown). NKSF induced antiviral activity and IFN-y produc-
tion by both total and sIg - splenocytes in a dose-dependent
manner and synergized with rIL2 in this effect.
NKSF"
rIL-2
(10' U/ml)
Total
Exp. 1
splenocytes
Exp. 2 Exp. 3
sIg -
spleno-
cytes
Ulmlt
None - 0 0 0 4
+ 8 4 4 2
0.2 U/ml - 8 2 8 2
+ 32 32 8 32
0.02 U/ml - 8 8 8 32
+ 64 32 128 64
2 x 10-' U/ml - 0 0 0 2
+ 32 2 16 16
2 x 10-" U/ml - 0 0 0 2
+ 16 2 2 4
None 1 .9±0.55 0.8±0.4
rIL-2, 100 U/ml 77 .3 ± 17.5 74.0 ± 41.0
NKSF, 1 U/ml 44.0 ± 10.5 41 .0 ± 22.5
rIL-2 + NKSF 875.3 ± 63.0 930.0 ± 116 .0Figure 5 .
￿
IFN-ymRNA accumulation in PBL and PHA-activated blasts
stimulated with NKSF. (A) (Top panel) PBL (solid ban) andPHA blasts
(dottedban)were incubated with 2 .5 U/ml semi-purifiedNKSF, 100 U/ml
rIIT2, orNKSF plus rIIr2 . Cell-free supernatants were assayed for IFN-y
by RIA . (Bottom panel) RNA were extracted from cells at various time
points after incubation with NKSF and/or rIIT2 and analyzed by Northern
blot using acDNA probe for human IFN-y . (B)PHA blasts (5 x 106/ml)
were stimulated for 18 h with 1.25 U/ml purified NKSF, 100 U/ml rIL2,
orNKSF plus rIL2 . Cell-free supernatants were assayed for IFN-y produc-
tion by RIA . Cytoplasmic RNA were analyzed by Northern blot .
Discussion
The possibility thathuman B lymphoblastoid cell lines pro-
duce factor(s) affecting lymphocyte functions was suggested
by their ability to facilitate IL2-dependent proliferation of
bothT andNK cells in vitro (29-31). During studies in which
lymphotoadn production by these cell lines was characterized
(22), we identified a novel cytokine that we defined NKSF
(1) . NKSF was purified 9,200-fold to near homogeneity from
the supernatant fluid of phorbol diester-induced cells of the
EBVtransformed human lymphoblastoid cell line, RPMI
8866, on the basis of its ability to induce IFN-y production
by human PBL (1) .
NKSF, when added to freshly isolated nonadherent PBL
in an 18-h culture, induces IFN-y production in a dose-
dependent manner that is only partially inhibited (22% on
average) by anti-IL-2 antiserum . In addition, as reported ear-
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lier, NKSF strongly synergizes with 11,2 in inducingIFN-y
at all concentrations of rIL2 tested (1) . These observations
exclude the possibility that IFN-y is indirectly induced by
NKSF via the induction of IL2 . Since IFN-y production in-
duced byNKSF was partially inhibited by anti-IIr2 antiserum,
this inhibition is probably due to minimal concentrations of
11,2 produced constitutively by PBL which enhances the
IFN-y production induced by NKSF. We did not detect
significant IL-2 message by standard Northern blotting tech-
niques in induced and uninduced lymphocytes. NKSF also
synergizes with other IFN-T inducers such as PHA and
phorbol diesters; the quantities of IFN-y induced in these
cultures range between 3-10-fold over levels expected for an
additive effect . In addition, endogenously produced IL2 does
not appear to be responsible for this synergy. However, a partialinhibition of the phorbol diester-induced IFN-y production
by anti-IL2 antiserurn suggests that IIr2 productionmay play
some role in inducing IFN-y production in these cultures.
Solid-phase linked anti-CD3 antibodies induce IFN-y
productionin PBL and this effect is synergistic with NKSF
during an 18-h culture. The ability of NKSF to synergize
with signals transduced through the TCR is also indicated
by the powerful enhancement of IFN-y production observed
in allogeneic but not in autologous MLC in the presence of
NKSF. A signal transduction pathway activated through TCR
CD3 results in increased [Ca2
+]i and protein kinase C (PKC)
activation (32) . The Ca2+ ionophores, A23187 and iono-
mycin, which are strongly synergistic with phorbol diesters
(33), do not synergize with NKSF, suggesting that mecha-
nisms other than increased [Ca2
+]i are responsible for the
synergistic effect ofTCRCD3 stimulation with NKSF. Since
anti-CD3 antibodies, antigens, and PHA (34) act via the TCR
CD3 complex, and phorbol diesters activate PKC (35), a major
mechanism by which these inducers synergize with NKSF
may be through activation of PKC. The mechanism of syn-
ergy between NKSF and I1r2 is, however, probably depen-
dent on other pathways of signal transduction. Indeed, we
(Chan, S.H., M. Kobayashi, D. Santoli, B. Perussia, and G.
Trinchieri, manuscript submitted for publication) have ob-
served major differences in the molecular mechanisms bywhich
11,2 and phorbol diesters synergize with NKSF in inducing
IFN-y.
CsA has been proposed to suppress early events governing
T cell activation, such as IL2 transcription, by inhibiting the
activity of DNA binding proteins in response to antigen
receptor triggering (27). C&A does not inhibit IFN-y produc-
tion by PBL induced with NKSF or 1172, alone or in combi-
nation, but almost completely abolishes the IFN-y produc-
tion induced by anti-CD3 and partially inhibits the IFN-y
production induced by PHA or phorbol diester, as well as
the synergy between NKSF and these inducers. Taken to-
gether, these results suggest that NKSF functions through
a different cell surface receptor and intracellular signal trans-
duction pathway than each ofthe inducers tested. The ability
of human NKSF to induce IFN-y production by murine
splenocytes suggests that receptors crossreacting with the
human cytokine are also present on murine lymphocytes.
Previous studies have shown that T and NK cells are the
only producers of IFN-y during an immune response (7-9).
NKSF induces IFN-y from both T and NK cells and syner-
gizes with rIlr2 in both cell types. To mediate this activity
on fresh PBL, NKSF requires the presence of nonadherent
HLA-DR' accessory cells. If HLADR- cells are recon-
stituted with HLA-DR+ cells, which do not make IFN-y,
they become responsive to NKSF. The accessory cells are not
monocytes because monocyte-depleted cells can still respond
to NKSF and HLA-DR - cells reconstituted with adherent
monocytes do not produce IFN-y when stimulated with
NKSF. This observation is consistent with those by others
(36-41) which demonstrate that IFN-y induction by other
stimuli also requires the presence of HLADR+ accessory
cells. Various cell types have been implicated as accessory cells.
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Antigen (42) or mitogen-induced (36, 43) activation of T
lymphocytes generally requires the participation ofaccessory
cells such as macrophages/monocytes (37, 38), dendritic cells
(39, 44), or fibroblasts (40). Additionally, production ofIFN-y
from resting T cells and CD16+ large granular lymphocytes
in response to I1r2 stimulation requires the presence ofHLA
DR+ accessory cells; these cells have been described as
nonadherent, esterase-negative monocytes and/or dendritic
cells (41). The nature of the accessory cells in our system is
unclear. Dendritic cells are necessary for specific antigen-
induced IFN-y production by T cells (our unpublished ob-
servation); they are loosely adherent cells and are present in
the adherent leukocyte population that is unable to support
NKSF action. We had identified a nonadherent HLADR+
light density cell type which, in addition to producing IFN-oc
in response to virus infection, acts as accessory cells for NK
cell cytotoxicity against virus-infected cells (45, 46). The
reported characteristics ofthese cells are consistent with those
of the accessory cells required for NKSF activity. The role
played by the accessory cells is unclear. We have not deter-
mined whether NKSF acts on freshly isolated PBL directly
(i.e., via receptors for NKSF expressed on the IFN-y-pro-
ducing cells which require additional signals from HLA-
DR+ cells), or indirectly (i.e., via receptors for NKSF ex-
pressed on HLADR+ accessory cells which in turn activate
the IFN-y-producing cells). However, the apparent lack of
accessory cell requirement in activated T or NK cell prepara-
tions and, more convincingly, the ability of a leukemic T
cell line to respond to NKSF (Chan, S.H., M. Kobayashi,
D. Santoli, B. Perussia, and G. Trinchieri, manuscript sub-
mitted for publication) strongly suggest that NKSF acts
directly on the ON-y-producing cells.
NKSF induces IFN-y production in both T and NK cells,
as clearly shown by the results obtained using enriched and
purified preparations of the two cell types from both fresh
and cultured PBL. The results of in situ hybridization per-
formed on T (CD3+ CD16-) and NK (CD3- CD16+)
cells, positively and negatively selected from PBL after stim-
ulation with NKSF and/or 11,2, confirm the ability ofboth
cell types to respond to NSKF. T and NK cells stimulated
with NKSF plus IL2 contain much higher numbers of grains
per cell than cells stimulated with either cytokine alone, sug-
gesting that synergy between NKSF and IL2 is largely due
to the synergistic accumulation of IFN-y mRNA in individual
cells. A higher number of cells accumulating IFN-y mRNA
is observed, however, in samples stimulated with both in-
ducers than with one alone. This observation may depend
on the sensitivity of the detection system which may not have
detected cells expressing very low levels of IFN-y mRNA
in cells induced with one lymphokine alone.
The observation, by in situ hybridization analysis, that
<20% ofPBL accumulate detectable levels of IFN-y mRNA
in response to NKSF and/or IL2, suggests that only a small
proportion of PBL are induced to accumulate mRNA and
secrete IFN-y at a given time. Our results are consistent with
those of Wilson et al. (41), who demonstrated through im-
munofluorescent staining for IFN-y that only 5 to 20% ofnormal lymphocytes synthesize IFN-y in primary cultures
with rIIr2. Qui et al. (13) also showed that <20% ofPBMC
accumulated IFN-y mRNA when stimulated with different
stimuli, as detected by in situ hybridization. The observa-
tion that only a small proportion of lymphocytes respond
to different stimuli with IFN-y productionis difficult to ex-
plain. At present, no specific subset of human T and NK
cellshas been demonstrated to preferentially produce IFN-y.
The small proportion of IFN-y-producing cells may be due
to discrete PBL subsets which express receptors for the var-
ious IFN-y inducers, a heterogeneity in the ability of PBL
to express receptors or to produce IFN-y, or a proportion
of activated lymphocytes present in PBL which either ex-
press increased numbers of receptors or an increased efficiency
in IFN-y production. The latter possibility is unlikely, how-
ever, because similarly small proportions of IFN-y-producing
cells were detected by in situ hybridization of PHA-activated
blasts stimulated with NKSF and IIr2 (our unpublished ob-
servation).
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